Day: January 5, 2026

The new location strengthens Amerant’s presence in one of Miami-Dade’s most vibrant residential and business communitiesAmerant Bank Bay Harbor Banking CenterBay Harbor Banking CenterCoral Gables, FL, Jan. 05, 2026 (GLOBE NEWSWIRE) — Amerant Bank, Florida’s bank of choice with a growing footprint throughout the state, announces the opening of its new Bay Harbor Banking Center, located at 1050 Kane Concourse. The new location advances Amerant’s strategic expansion across South Florida, strengthening its commitment to serving clients in high-growth and relationship-driven markets. Located along Kane Concourse, the main commercial corridor of Bay Harbor Islands, the 1,300-square-foot banking center is designed to conveniently serve residents, professionals, and local businesses in the surrounding waterfront community. The...

Neve Yarak, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. (“Solterra”). As announced on December 29, 2025, key milestones in Germany project, which includes solar energy PV and storage assets, have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality. Key Investor HighlightsReduction in permitting and regulatory risk across core European assets Advanced payment of $340,000 and receiving favourable terms in the project’s profit stake Approximately $1.7 million in project-level...

KISSIMMEE, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) — ECD Automotive Design, the world’s largest Land Rover and Jaguar restoration company known for its bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs, Toyota FJs, and the ECDXCTC INEOS Grenadier and Defender II, announces Project Wrangler, a Defender 110 Soft Top designed for drivers who value mechanical engagement, open-air freedom, and intentional craftsmanship. Built on the D110 platform, Project Wrangler blends classic Defender character with modern performance, placing the driving experience at the forefront. Images of Project Wrangler Video of Project Wrangler At its core is a 6.2L LT1 V8 paired with a close-ratio Magnum T56 six-speed manual transmission, an increasingly rare combination that restores true driver involvement. Power is controlled with confidence...

Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa’s proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. “This is an important milestone because it allows us to assess whether NGC-Cap can demonstrate a meaningful improvement over capecitabine monotherapy in both safety and efficacy for patients who have already undergone multiple prior cancer treatments.,” said George Ng, Chief Executive...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard pharmaceutical format for this compound. Conversion to the hydrochloride salt improves stability, solubility, purity, and dosing precision, aligning...

Initiation of eAArly DETECT 2 – U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectStudy Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2026 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments for the year ended December 31, 2025. The Company expects to release its year-end financial results in March 2026. Key Highlights During 2025 Colorectal Cancer Business HighlightsMainz Biomed launched eAArly DETECT 2,...

The acquisition, which is subject to closing conditions, would encompass Quantum’s proprietary intellectual property portfolio, including an innovative patent for AI-Quantum Error Correction Tel Aviv, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) — Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, today announced that it has received the requisite stockholder approval via written consent of the majority of its stockholders (the “Stockholder Consent”) for its previously announced acquisition of Quantum X Labs Ltd. (“Quantum”), a multi-disciplinary quantum technology hub focused on quantum algorithms, navigation, and atomic clocks. The acquisition, which was entered into pursuant to the definitive share purchase agreement dated December 15, 2025 (the “Agreement Date”), involves Viewbix acquiring...

Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products. The study, conducted using a validated in-vitro Transwell permeability system designed to mimic allergen transfer into the nasal mucosa, assessed PL-14’s ability to inhibit transfer of Der p 1, a major clinically relevant house dust mite allergen commonly associated with allergic rhinitis and asthma. Key findings demonstrated that PL-14 significantly...

AI trailblazer to bring its MCP and A2A-optimized Amelia 7 agentic platform to global automakers; Also debuts new groundbreaking Vision AI for vehiclesSANTA CLARA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, today announced that it’s bringing the full power of its Amelia 7 agentic AI to vehicles, TVs, and smart devices – enabling a significantly expanded voice commerce marketplace, with AI agents that can order food, make dinner reservations, pay for parking, book tickets, travel, and more. These new capabilities are being showcased for the very first time at CES 2026 [West Hall, Booth #5867], alongside the company’s first ever live demo of Vision AI for vehicles. Agentic Voice Commerce Expansion SoundHound’s AI agent orchestration platform brings...

Englewood, New Jersey, US, Jan. 05, 2026 (GLOBE NEWSWIRE) — Odysight.ai Inc. (NASDAQ:ODYS), a leader in AI-powered visual sensing and Predictive Maintenance (PdM) technologies, today announced that it had posted a CEO letter to shareholders on the Company’s investor relations website at https://www.odysight.ai/. The CEO letter to shareholders is reproduced below. Dear Shareholders, As Odysight.ai continues to build its position at the intersection of deep tech, aerospace, defense, and industrial AI, the past year has marked an important phase in our evolution. With rising global defense investment and accelerating AI adoption, we have advanced our strategy, strengthened our capabilities, and delivered meaningful progress. Three years ago, I stepped into the role of CEO with a clear objective: to make Odysight.ai a leader in deep...